Abstract 3987
Background
There is a global consensus that at the end of life relief of symptoms and suffering must be guaranteed. It is considered by our national health system as a priority goal in advanced cancer to address all the needs both the patient and the family, and improve their quality of life. Palliative Care Units (PCU) are intended to achieve this objective. In the last months of life, despite these advances, active treatments continue to predominate over palliative care.
Methods
We conducted a retrospective observational study selecting all patients with a first consultation in the Medical Oncology Unit of the Puerta de Hierro University Hospital during 2014 and 2015, who died before December 31st, 2017. Treatments carried out, assessment by a PCU and home palliative care services (HPCS), during the last 6 months of life and place of death (hospital, home or PCU) were reviewed. We aim to assess quality of care evaluating the use of active therapies and PCU using a novel approach considering what was done during the last six months of life.
Results
622 patients were selected (36% female/64% male), median age of 69 years (IQR 61-76). 89% were stage IV. Lung (32%) and gastrointestinal (31%) cancer were the most frequent. In the last 6 months of life, 59% of patients received chemotherapy (CT), 26% radiotherapy (RT) and 8% undergone surgery. Median time from the last CT and RT to death was 39 days (IQR 23-75) and 57 days (IQR 21-100) respectively. 28% of patients were not assessed by a PCU from whom 52% were first evaluated in the last 30 days before death and 28% had been followed for more than 60 days. Only 44% were followed by HPCS. In patients with HPCS, the number of deaths at home (41%) and at PCU (29%) was significantly higher, with only 30% dying at hospital. By contrast, among those never assessed by HPCS: these figures were 12%, 24% and 64% respectively (p < 0,001).
Conclusions
1/3 of patients had never been assessed by a PCU and the selection of patients who benefit from active therapies in the last months of life must be clearly improved. The association between place of death and assessment by a HPCS suggests the efficiency of these units and the benefit of increasing their resources. The objective of a global approach for palliative care to all patients with advanced cancer is close but not achieved yet.
Clinical trial identification
Legal entity responsible for the study
Medical Oncology Department, Puerta de Hierro University Hospital.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract